Pfizer's Lipitor Provides Greater Reductions in Heart Attack, Stroke and Cardiovascular Procedures at an Overall Cost Savings Compared to Zocor, New Analysis Shows

* Major Study Shows That One Out of Every Six Heart Attacks, Strokes and

Cardiovascular Procedures Could be Avoided for Heart Disease Patients

Treated With Intensive Lipitor 80mg Therapy Vs. Standard Dose Zocor

* Even If the Current U.S. Price of Zocor Were Reduced by 50 Percent,

Lipitor Patients Could Still Achieve the Greater Cardiovascular Benefits

Seen in This Study at a Cost Savings for Payors

* Dr. Peter Lindgren: "This analysis suggests that the cost of using

Lipitor versus generic simvastatin could represent a good value for money"

* Lipitor Study Further Supports New AHA/ACC Guidelines for Secondary

Prevention-LDL-Cholesterol of Less than 100 mg/dL for all Patients With

Coronary Heart Disease

May 15, 2006, 01:00 ET from Pfizer Inc

    NEW YORK, May 15 /PRNewswire-FirstCall/ -- Pfizer Inc said today that a
 new economic analysis that compares outcomes for patients taking Lipitor to
 those taking Zocor shows that Lipitor patients had greater reductions in
 heart attacks, strokes and cardiovascular procedures. This provides a cost
 savings for payors in long-term hospitalizations and surgical costs.
     The economic analysis examined the results from the IDEAL (Incremental
 Decrease in Endpoints Through Aggressive Lipid Lowering) trial to analyze
 the cost effectiveness of treatment with Lipitor and Zocor (simvastatin) in
 Sweden, where Zocor is available generically as simvastatin. The IDEAL
 patients who received Lipitor (80 mg) achieved greater reductions in heart
 attacks, strokes and cardiovascular procedures compared to patients taking
 standard dose Zocor (20-40 mg).
     The results also showed that one out of every six heart attacks,
 strokes or cardiovascular procedures could be avoided for coronary heart
 disease patients treated with intensive Lipitor therapy above and beyond
 those treated with Zocor over 4.8 years.
     These results were then applied to the U.S. health care system, with
 two key findings:
     * Better efficacy was achieved in patients taking Lipitor, at a better
       overall value, compared to patients on standard Zocor therapy; and
     * Patients taking Lipitor achieved greater reductions in cardiovascular
       events, and the system had overall cost savings, compared to patients
       taking Zocor at the current U.S. price, and even when Zocor was
       discounted by 50 percent.
     In the U.S., cardiovascular disease remains the nation's leading health
 threat, and accounts for an estimated 500,000 recurrent heart attacks and
 200,000 recurrent debilitating strokes annually.
     "The economic impact of heart attacks and strokes in the U.S. alone
 totals nearly $403 billion in medical care and lost productivity annually,"
 said Dr. Peter Lindgren, Stockholm Health Economics. "This analysis
 suggests that the cost of using Lipitor versus generic simvastatin could
 represent a good value for money."
     "Even if the current U.S. price of Zocor were reduced by 75 percent,
 Lipitor patients could still achieve better cardiovascular outcomes at an
 increase to payors of less than one dollar a day," said Dr. Gregg Larson,
 vice president cardiovascular medical at Pfizer. "While the economic cost
 of a stroke can be exorbitant, often entailing years of rehabilitation and
 supervised care the emotional impact on patients and their families is also
     The IDEAL economic analysis assessed the cost-effectiveness of
 preventing cardiovascular events for patients who took intensive Lipitor
 therapy versus standard dose Zocor. The analysis compared the total cost
 per patient for 4.8 years in each treatment group by calculating medication
 costs, the cost of hospitalizations associated with cardiovascular events
 and lost work days for the U.S. and for Sweden. The cost of Lipitor was
 compared to the cost of generic simvastatin for Sweden. For the U.S., the
 cost of Lipitor was compared to Zocor in three scenarios, including:
     * Lipitor compared to the current U.S. price of Zocor (simvastatin);
     * Lipitor compared to a 50% reduction in the current U.S. price of Zocor;
     * Lipitor compared to a 75% reduction in the current U.S. price of Zocor.
     "IDEAL, which is one of a limited number of head to head statin therapy
 trials showed that patients using intensive atorvastatin therapy compared
 with standard dose simvastatin suffered fewer cardiovascular events. The
 findings in IDEAL, along with other positive studies of intensive
 atorvastatin therapy against active treatment comparitors such as AVERT,
 PROVE-IT, REVERSAL and ALLIANCE, indicate that all statin therapy in not
 alike," said Dr. Michael Koren, director of non-invasive cardiology at
 Memorial Hospital in Jacksonville, Florida. "Switching patients from
 atorvastatin to other less effective drugs could have negative health
 implications for patients. The IDEAL pharmacoeconomic analysis makes the
 case that drug cost savings from use of generic statins may be largely
 offset by higher patients care and indirect costs."
     The results were presented at the annual American Heart Association
 Quality of Care and Outcomes Research Meeting in Washington, D.C., and a
 summary of the data was published in the current issue of "Circulation."
     The newly announced American Heart Association (AHA) and American
 College of Cardiology (ACC) guidelines on secondary prevention further
 support LDL reduction. The new guidelines recommend that LDL-cholesterol
 should be less than 100 mg/dL for all patients with CHD and other forms of
 atherosclerosis vascular disease. In the IDEAL study, patients treated with
 Lipitor achieved average LDL-cholesterol levels of 81 mg/dL which was
 significantly lower than patients taking Zocor, who had an average
 LDL-cholesterol level of 104 mg/dL.
     Lipitor is the most prescribed cholesterol-lowering therapy in the
 world, with nearly 115 million patient-years of experience.
     Lipitor is a prescription drug. It is used in patients with multiple
 risk factors for heart disease such as family history, high blood pressure,
 age, low HDL or smoking to reduce the risk of heart attack and stroke. When
 diet and exercise alone are not enough, Lipitor is used along with a
 low-fat diet and exercise to lower cholesterol.
     Lipitor is also used in patients with type 2 diabetes and at least one
 other risk factor for heart disease such as high blood pressure, smoking or
 complications of diabetes, including eye disease and protein in urine, to
 reduce the risk of heart attack and stroke.
     Lipitor is not for everyone. It is not for those with liver problems.
 And it is not for women who are nursing, pregnant or may become pregnant.
     If you take Lipitor, tell your doctor if you feel any new muscle pain
 or weakness. This could be a sign of rare but serious muscle side effects.
 Tell your doctor about all medications you take. This may help avoid
 serious drug interactions. Your doctor should do blood tests to check your
 liver function before and during treatment and may adjust your dose. The
 most common side effects are gas, constipation, stomach pain and heartburn.
 They tend to be mild and often go away.
     For additional product information, visit

SOURCE Pfizer Inc